Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for ABBV-932 Clear all
Completed Phase 2 Interventional

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Dothan, Alabama • Anaheim, California • Colton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 25, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

NCT06846320
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
49
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 25, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239
View directory record Official record
Conditions
Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 25, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

NCT05738850
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions
ABBV-932, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 25, 2026, 1:05 AM EDT